Chinese Communist Party Visa Disclosure Act of 2025 or the CCP Visa Disclosure Act of 2025This bill requires an applicant for an F, J, or M (student or exchange visitor) visa to disclose in the application certain information about whether the applicant has received or will receive funds from the Chinese government, the Chinese Communist Party (CCP), or an entity controlled by either. If an individual receives such funds after receiving such a visa, the individual must inform the Department of Homeland Security and the Department of State.Any visa issued to an individual who violates these disclosure requirements may be revoked.
Student Visa Security Improvement ActThis bill establishes new requirements for foreign student visas and participating educational institutions. The Department of Homeland Security (DHS) must review the applications of student visa applicants and conduct in-person interviews when appropriate to determine whether they are inadmissible due to terrorist-related activities. DHS must also conduct on-site reviews of applications and supporting documents deemed appropriate prior to final adjudication.Institutions and exchange student visitor programs must ensure that student visa-holders are active participants in the program. Students must be regularly observed and must be reported on if they transfer or change majors. The bill also provides for enhanced access to the Student and Exchange Visitor Information System for institutions and programs that meet staffing and training requirements.The Government Accountability Office must review the fees for the Student and Exchange Visitor program.
State Border Security Reimbursement Act of 2025 This bill requires the federal government to reimburse eligible states for their border security expenses.To be eligible, a state must have expended more than $2.5 billion on border security and enforcement in the 10 years before this bill's enactment. If such a state provides by a certain deadline an accounting of all of its nonfederally funded border security expenses, the federal government must reimburse the full amount.
End Child Trafficking Now ActThis bill imposes restrictions related to adult non-U.S. nationals (aliens under federal law) being admitted into the United States with a minor.Such an adult may not be admitted with a minor unless the adult (1) presents documents and witness testimony proving that the adult is a relative or guardian of the minor, or (2) submits to a DNA test that proves such a relationship. The Department of Homeland Security may request a DNA test only if the required relationship cannot be established by the presented documents and witness testimony. An adult who does not consent to a requested DNA test shall be inadmissible.If the required relationship cannot be established and the immigration officer believes the adult is guilty of a felony offense, the officer may arrest the adult.The bill makes it a crime for an adult to knowingly use a minor to whom the adult is not a relative or guardian to enter the United States.
Skinny Labels, Big Savings ActThis bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics.The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act:submitting or seeking approval of a skinny label for a generic or biosimilar drug;promoting or commercially marketing a drug with skinny labeling approved by the FDA; ordescribing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug.The bill also applies the safe harbor to similar actions under the Public Health Service Act.